Abstract
Current and future clinical applications of the Human Tumour Clonogenic Cell Culture (HTC 3) system are presented. Advanced gynaecological cancers, especially ovarian, endometrial and cervical carcinomas, require extensive systemic chemotherapy. The HTC 3 system seems to be an adequate instrument for individualized chemosensitivity testing in order to choose proper cytostatic treatments; that is, maximum tumour cell kill with minimal side-effects. Furthermore, this system helps in assessing the response after treatment by detection of remaining clonogenic, and thus viable, tumour cells. Other clinical applications of the system include grading of the tumour and recognition of the histologie type. Thus the HTC 3 provides a potential tool in diagnosis, treatment and follow-up of gynaecologic malignancies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
